FDA grants AP status for Neurocrine's Ingrezza Sprinkle (NDA218390)
The FDA has granted approval status (AP) for Neurocrine's Ingrezza Sprinkle under application NDA218390, with a submission type of SUPPL.
Therapeutic Area
Therapeutic area intelligence for Movement Disorders with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has approved a supplemental application for deutetrabenazine submitted by Aurobindo Pharma.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.